Article

EGFR Mutation Subtype and Risk of Brain Metastases from Non-Small Cell Lung Cancer in the Osimertinib Era

2025-11-03

Abstract excerpt

<title>Abstract</title> <p> <bold>Background:</bold> Mutations in the EGFR gene are common in lung adenocarcinoma and can be targeted by tyrosine kinase inhibitors (TKIs). However, many patients eventually develop brain metastases, which are difficult to treat because the blood–brain barrier (BBB) restricts the entry of most TKIs into the central nervous system. Previous studies have suggested that tumors with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a3daff62-aa8b-5034-842a-bb0df620efe4
DOI: 10.21203/rs.3.rs-7992311/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

EGFR Mutation Subtype and Risk of Brain Metastases from Non-Small Cell Lung Cancer in the Osimertinib EraDOI 10.21203/rs.3.rs-7992311/v1Read

Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.Semantic proximity Read

Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.Semantic proximity Read

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR MutationsSemantic proximity Read

Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung.Semantic proximity Read

Correlation of EGFR mutation subtypes and survival in surgically treated brain metastasis from non-small-cell lung cancer.Semantic proximity Read

Impact of EGFR Mutation Subtypes and TKI Generations on Clinical Outcomes in Lung Adenocarcinoma Patients with Brain Metastases Treated with Gamma Knife RadiosurgerySemantic proximity Read

A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma: a rare EGFR alteration reportSemantic proximity Read

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC.Semantic proximity Read

Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer.Semantic proximity Read

Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations.Semantic proximity Read

Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases.Semantic proximity Read

A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.Semantic proximity Read